CL2019002324A1 - Imidazo-quinolinas sustituidas como moduladores de receptores tipo dominio de oligomerización de fijación a nucleótidos p3 (nlrp3). - Google Patents

Imidazo-quinolinas sustituidas como moduladores de receptores tipo dominio de oligomerización de fijación a nucleótidos p3 (nlrp3).

Info

Publication number
CL2019002324A1
CL2019002324A1 CL2019002324A CL2019002324A CL2019002324A1 CL 2019002324 A1 CL2019002324 A1 CL 2019002324A1 CL 2019002324 A CL2019002324 A CL 2019002324A CL 2019002324 A CL2019002324 A CL 2019002324A CL 2019002324 A1 CL2019002324 A1 CL 2019002324A1
Authority
CL
Chile
Prior art keywords
disease
nlrp3
quinolines
receptor modulators
nucleotide binding
Prior art date
Application number
CL2019002324A
Other languages
English (en)
Inventor
Glick Gary
Ghosh Shomir
R Roush William
James Olhava Edward
Danielo'malley
Original Assignee
Innate Tumor Immunity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61283434&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019002324(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innate Tumor Immunity Inc filed Critical Innate Tumor Immunity Inc
Publication of CL2019002324A1 publication Critical patent/CL2019002324A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

ENTIDADES QUÍMICAS (POR EJEMPLO, UN COMPUESTO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE, Y/O UN HIDRATO, Y/O UN COCRISTAL, Y/O UNA COMBINACIÓN FARMACOLÓGICA DEL COMPUESTO) QUE MODULAN (POR EJEMPLO, AGONIZAN O PARCIALMENTE AGONIZAN) NLRP3 QUE SON ÚTILES PARA TRATAR UNA AFECCIÓN, UNA ENFERMEDAD O UN TRASTORNO EN DONDE UN AUMENTO EN LA TRANSDUCCIÓN DE SEÑAL DE NLRP3 PUEDE CORREGIR UNA DEFICIENCIA EN LA ACTIVIDAD INMUNITARIA INNATA (UNA AFECCIÓN, UNA ENFERMEDAD O UN TRASTORNO ASOCIADO A UNA RESPUESTA INMUNITARIA INSUFICIENTE) QUE CONTRIBUYE A LA PATOLOGÍA Y/O LOS SÍNTOMAS YIO LA PROGRESIÓN DE LA AFECCIÓN, LA ENFERMEDAD O E! TRASTORNO (CÁNCER) EN UN SUJETO (UN SER HUMANO). TAMBIÉN COMPOSICIONES, ASÍ COMO OTROS MÉTODOS DE USO Y FABRICACIÓN DE ESTAS.
CL2019002324A 2017-02-17 2019-08-16 Imidazo-quinolinas sustituidas como moduladores de receptores tipo dominio de oligomerización de fijación a nucleótidos p3 (nlrp3). CL2019002324A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762460677P 2017-02-17 2017-02-17
US201762490881P 2017-04-27 2017-04-27
US201762573991P 2017-10-18 2017-10-18

Publications (1)

Publication Number Publication Date
CL2019002324A1 true CL2019002324A1 (es) 2019-11-29

Family

ID=61283434

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002324A CL2019002324A1 (es) 2017-02-17 2019-08-16 Imidazo-quinolinas sustituidas como moduladores de receptores tipo dominio de oligomerización de fijación a nucleótidos p3 (nlrp3).

Country Status (29)

Country Link
US (4) US10533005B2 (es)
EP (2) EP3753938B1 (es)
JP (1) JP7003143B6 (es)
KR (1) KR102329062B1 (es)
CN (1) CN110325534B (es)
AU (1) AU2018221076B2 (es)
BR (1) BR112019016625A2 (es)
CA (1) CA3053949A1 (es)
CL (1) CL2019002324A1 (es)
CO (1) CO2019008932A2 (es)
CY (1) CY1123305T1 (es)
DK (1) DK3510034T3 (es)
ES (1) ES2799900T3 (es)
HR (1) HRP20201087T1 (es)
HU (1) HUE050965T2 (es)
IL (1) IL268640B (es)
LT (1) LT3510034T (es)
ME (1) ME03801B (es)
MX (1) MX2019009788A (es)
MY (1) MY194054A (es)
PE (1) PE20191552A1 (es)
PL (1) PL3510034T3 (es)
PT (1) PT3510034T (es)
RS (1) RS60548B1 (es)
SG (1) SG11201907451XA (es)
SI (1) SI3510034T1 (es)
TW (1) TWI674261B (es)
WO (1) WO2018152396A1 (es)
ZA (1) ZA201906104B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11225486B2 (en) 2017-10-18 2022-01-18 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2018009916A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
BR112020000523A2 (pt) 2017-07-14 2020-07-14 Innate Tumor Immunity, Inc. moduladores de nlrp3
US11203579B2 (en) 2017-07-24 2021-12-21 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
JP2020531453A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
UY37848A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3837015B1 (en) 2018-08-16 2024-02-14 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
ES2930171T3 (es) * 2018-08-16 2022-12-07 Innate Tumor Immunity Inc Moduladores de NLRP3 derivados de imidazo[4,5-C]quinolina
JP2021534180A (ja) 2018-08-16 2021-12-09 イネイト・テューマー・イミュニティ・インコーポレイテッドInnate Tumor Immunity, Inc. 置換４−アミノ−１Ｈ−イミダゾ［４，５−ｃ］キノリン化合物およびその製造の改良法
CN111253390B (zh) * 2018-11-30 2023-10-03 四川科伦博泰生物医药股份有限公司 并环化合物、其制备方法及用途
EP3911641A1 (en) * 2019-01-14 2021-11-24 Innate Tumor Immunity, Inc. Nlrp3 modulators
KR20210114983A (ko) * 2019-01-14 2021-09-24 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
CN113195469A (zh) 2019-02-19 2021-07-30 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US11744874B2 (en) * 2019-12-20 2023-09-05 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
KR102409345B1 (ko) * 2020-09-22 2022-06-16 가톨릭대학교 산학협력단 Nlrp3 인플라마좀 억제제 및 이의 용도
CN116874340B (zh) * 2023-07-10 2024-04-05 湖北航天化学技术研究所 一种苯基***类含能共晶化合物及其制备方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US948029A (en) * 1909-04-23 1910-02-01 James Harvey Leffler Reclining-chair.
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
SG46492A1 (en) * 1991-03-01 1998-02-20 Minnesota Mining & Mfg 1-Substituted 2-substituted 1H-imidazo [4,5-c] quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JPH1180156A (ja) 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体
ES2340745T3 (es) 1998-12-23 2010-06-08 Pfizer Inc. Anticuerpos monoclonales humanos contra ctla-4.
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
MXPA05006740A (es) 2002-12-20 2005-10-05 3M Innovative Properties Co Imidazoquinolinas arilo-sustituidas.
WO2004071459A2 (en) 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
WO2005018555A2 (en) 2003-08-14 2005-03-03 3M Innovative Properties Company Lipid-modified immune response modifiers
KR101106812B1 (ko) 2003-08-27 2012-01-19 쓰리엠 이노베이티브 프로퍼티즈 컴파니 아릴옥시 및 아릴알킬렌옥시 치환된 이미다조퀴놀린
EA200600540A1 (ru) 2003-09-05 2006-08-25 Анадис Фармасьютикалз, Инк. Введение лигандов tlr7 и их пролекарств для лечения инфекции вируса гепатита с
JP4891088B2 (ja) 2003-11-25 2012-03-07 スリーエム イノベイティブ プロパティズ カンパニー 置換されたイミダゾ環系および方法
TW200533352A (en) 2003-12-04 2005-10-16 3M Innovative Properties Co Sulfone substituted imidazo ring ethers
WO2005094531A2 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
JP2007530579A (ja) 2004-06-10 2007-11-01 スリーエム イノベイティブ プロパティズ カンパニー アミド置換イミダゾピリジン、イミダゾキノリン、およびイミダゾナフチリジン
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US20070259881A1 (en) 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
MX2007003078A (es) 2004-09-14 2007-05-16 Novartis Vaccines & Diagnostic Compuestos de imidazoquinolina.
EP1835915A4 (en) 2004-12-30 2010-02-24 Coley Pharm Group Inc IMMUNE REACTION MODIFIER FORMULATIONS AND RELATED METHODS
JP2008532933A (ja) * 2005-02-11 2008-08-21 コーリー ファーマシューティカル グループ，インコーポレイテッド 置換イミダゾキノリン類および置換イミダゾナフチリジン類
EP1851218A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
WO2006098852A2 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
WO2007079086A1 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
DK2155743T3 (da) 2007-05-08 2012-11-05 Astrazeneca Ab Imidazoquinoliner med immunmodulerende egenskaber
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
EP2009002A1 (en) 2007-06-21 2008-12-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
WO2010088924A1 (en) * 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR101573109B1 (ko) 2009-11-24 2015-12-01 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
US9034336B2 (en) * 2011-08-30 2015-05-19 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
CN115093480A (zh) 2012-05-31 2022-09-23 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
EP2674170B1 (en) * 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
US9295732B2 (en) 2013-02-22 2016-03-29 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
EP2992017B1 (en) 2013-05-02 2020-11-18 AnaptysBio, Inc. Antibodies directed against programmed death-1 (pd-1)
JP6453855B2 (ja) 2013-05-18 2019-01-16 アドゥロ バイオテック，インク． 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法
JP6563906B2 (ja) 2013-05-31 2019-08-21 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｐｄ−１に結合する抗原結合蛋白質
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
AU2013400609B9 (en) 2013-09-13 2020-03-05 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
US10654807B2 (en) 2013-12-20 2020-05-19 The University Of Kansas Toll-like receptor 8 agonists
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于***的抗-pd-l1结合物
GB201418004D0 (en) 2014-10-10 2014-11-26 Isis Innovation Polymer adjuvant
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
MA48579A (fr) 2015-09-01 2020-03-18 Agenus Inc Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
JP2018526013A (ja) 2015-09-01 2018-09-13 イネイト・テューマー・イミュニティ・インコーポレイテッドＩｎｎａｔｅ Ｔｕｍｏｒ Ｉｍｍｕｎｉｔｙ， Ｉｎｃ． 免疫または免疫抑制性サイトカインに対する抵抗性が増大した免疫細胞およびその使用
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于***的抗-egfr组合
US10730871B2 (en) 2016-01-28 2020-08-04 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN111491362B (zh) 2016-02-02 2023-10-24 华为技术有限公司 确定发射功率的方法、用户设备和基站
US10533007B2 (en) 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
AU2017252640A1 (en) 2016-04-19 2018-12-06 Innate Tumor Immunity, Inc. NLRP3 modulators
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11225486B2 (en) 2017-10-18 2022-01-18 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US11926630B2 (en) 2017-10-18 2024-03-12 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors

Also Published As

Publication number Publication date
US10533005B2 (en) 2020-01-14
ZA201906104B (en) 2021-05-26
JP7003143B6 (ja) 2024-02-26
US11827632B2 (en) 2023-11-28
CN110325534B (zh) 2024-04-05
EP3510034B1 (en) 2020-04-22
BR112019016625A2 (pt) 2020-04-14
KR20190117657A (ko) 2019-10-16
IL268640A (en) 2019-10-31
HRP20201087T1 (hr) 2020-10-30
EP3753938B1 (en) 2024-03-20
JP2020508302A (ja) 2020-03-19
IL268640B (en) 2021-12-01
SI3510034T1 (sl) 2020-11-30
SG11201907451XA (en) 2019-09-27
CO2019008932A2 (es) 2020-01-17
MX2019009788A (es) 2019-10-07
JP7003143B2 (ja) 2022-01-20
DK3510034T3 (da) 2020-07-27
EP3510034A1 (en) 2019-07-17
TW201835077A (zh) 2018-10-01
CY1123305T1 (el) 2021-12-31
LT3510034T (lt) 2020-08-10
PE20191552A1 (es) 2019-10-24
US20220289736A1 (en) 2022-09-15
US20200157096A1 (en) 2020-05-21
MY194054A (en) 2022-11-10
US20190055236A1 (en) 2019-02-21
TWI674261B (zh) 2019-10-11
AU2018221076A1 (en) 2019-10-03
ES2799900T3 (es) 2020-12-22
ME03801B (me) 2021-04-20
US20240067649A1 (en) 2024-02-29
WO2018152396A1 (en) 2018-08-23
HUE050965T2 (hu) 2021-01-28
KR102329062B1 (ko) 2021-11-18
NZ757257A (en) 2021-11-26
AU2018221076B2 (en) 2020-12-24
PL3510034T3 (pl) 2020-11-30
RS60548B1 (sr) 2020-08-31
EP3753938A1 (en) 2020-12-23
CA3053949A1 (en) 2018-08-23
PT3510034T (pt) 2020-06-23
CN110325534A (zh) 2019-10-11

Similar Documents

Publication Publication Date Title
CL2019002324A1 (es) Imidazo-quinolinas sustituidas como moduladores de receptores tipo dominio de oligomerización de fijación a nucleótidos p3 (nlrp3).
BR112018071347A2 (pt) moduladores de nlrp3
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
UY36757A (es) Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
CO2017000510A2 (es) Constructos de car
CO2018000809A2 (es) Anticuerpos para cd40
EA201891565A1 (ru) Соединения и композиции для лечения состояний, ассоциированных с активностью sting
CO2019005236A2 (es) Métodos para tratar afecciones inflamatorias
AR093788A1 (es) Inmunoterapia con agentes de enlace
BR112018013074A2 (pt) terapias de célula efetora imune com eficácia real-çada
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
ECSP14026271A (es) Compuestos de indol e indazol que activan la ampk
EA202092581A1 (ru) Соединения, ингибирующие rip1, а также способы их получения и применения
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
BR112018000254A2 (pt) inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas
GT201700025A (es) Inhibidores de la proteína quinasa c y métodos de su uso
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
CL2019000799A1 (es) Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano. (divisional solicitud 201602433)
CL2017000053A1 (es) Anticuerpos de unión a protofibrillas aß
BR112017018872A2 (pt) combinação de um antagonista pd-1 e eribulina para tratamento de câncer
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
EA201692460A1 (ru) Антитела, направленные на cd127
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)